5 Love Languages for Malignancies

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Texas Oncology, Fort Worth, TX
Malignancies
5 Love Languages - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The objective of this study is to evaluate the effectiveness of an intervention utilizing the Five Love Languages on quality of life (pain, depression, and anxiety) of cancer patients.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Malignancies

Study Objectives

3 Primary · 1 Secondary · Reporting Duration: 6 weeks

6 weeks
Anxiety
Depression
Pain
Relationship Quality

Trial Safety

Safety Progress

1 of 3

Other trials for Malignancies

Trial Design

1 Treatment Group

Cancer Patient and their significant other
1 of 1
Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: 5 Love Languages · No Placebo Group · N/A

Cancer Patient and their significant other
Behavioral
Experimental Group · 1 Intervention: 5 Love Languages · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 weeks
Closest Location: Texas Oncology · Fort Worth, TX
Photo of texas 1Photo of texas 2Photo of texas 3
2003First Recorded Clinical Trial
1 TrialsResearching Malignancies
80 CompletedClinical Trials

Who is running the clinical trial?

University of Texas at AustinLead Sponsor
283 Previous Clinical Trials
67,191 Total Patients Enrolled
1 Trials studying Malignancies
60 Patients Enrolled for Malignancies

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.